- not yet recruitingPHASE3
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
This study is looking at a new medicine, AZD6234, for adults with Type 2 diabetes who are also overweight or have obesity. It aims to see how well it helps with weight loss and how safe it is compared to a dummy medicine.
United States · Argentina · Australia - recruitingPHASE3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
This study is testing a new medicine, enicepatide, for people who are overweight or have obesity but do not have type 2 diabetes. It aims to see if the medicine helps with weight loss and if it's safe compared to a dummy medicine.
United States · Argentina · Australia - recruitingPHASE3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
This study looks at a new medicine called enicepatide for people who are overweight or have obesity and also have type 2 diabetes. We want to see if it helps with weight loss and if it's safe to use.
United States · Argentina · Australia - not yet recruitingPHASE3
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
This study is testing a new medicine called AZD6234 for adults who are overweight or have obesity and other health issues, including some with type 2 diabetes. It aims to see if adding AZD6234 to their current weight management medicines helps them lose more weight safely.
United States · Argentina · Brazil - recruitingPHASE3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
This study looks at combining two medicines, mirikizumab and tirzepatide, for adults with ulcerative colitis (UC) who are also overweight or obese. The goal is to see if this combination helps UC symptoms improve and also leads to significant weight loss.
United States · Austria · Belgium - recruitingPHASE3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
This study looks at new medicines, mirikizumab and tirzepatide, for adults with Crohn's disease who are also overweight or have obesity. It wants to see if these treatments are safe and if they help manage Crohn's symptoms and potentially aid weight management.
United States · Austria · Belgium